Aktis Oncology (NASDAQ:AKTS) Stock Rating Upgraded by Wall Street Zen

Aktis Oncology (NASDAQ:AKTS) was upgraded by stock analysts at Wall Street Zen to a “hold” rating in a note issued to investors on Saturday.

Aktis Oncology Price Performance

AKTS opened at $19.75 on Friday. Aktis Oncology has a twelve month low of $19.02 and a twelve month high of $29.16.

Insider Transactions at Aktis Oncology

In related news, major shareholder Ansbert Gadicke purchased 1,112,777 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was purchased at an average price of $18.00 per share, with a total value of $20,029,986.00. Following the completion of the acquisition, the insider owned 10,260,064 shares in the company, valued at $184,681,152. This trade represents a 12.17% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Helen Susan Kim acquired 835,000 shares of the stock in a transaction on Monday, January 12th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $15,030,000.00. Following the purchase, the director directly owned 5,671,825 shares of the company’s stock, valued at $102,092,850. The trade was a 17.26% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have acquired 6,117,776 shares of company stock valued at $110,119,968. 3.30% of the stock is currently owned by company insiders.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.